Danaher Corp. (DHR) Misses Q3 EPS by 4c; Lowers FY12 EPS Outlook, Gudes Q4 EPS
Tweet
Share
E-mailGet Alerts DHR Hot Sheet
Price: $205.79 --0%
Financial Fact:
Selling, general and administrative expenses: -1.35B
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Selling, general and administrative expenses: -1.35B
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Danaher Corp. (NYSE: DHR) reported Q3 EPS of $0.77, $0.04 worse than the analyst estimate of $0.81. Revenue for the quarter came in at $4.42 billion versus the consensus estimate of $4.61 billion.
Danaher Corp. sees Q4 2012 EPS of $0.80-0.85, versus the consensus of $0.88.
Danaher Corp. sees FY2012 EPS of $3.14-3.19, versus prior guidance of $3.19-3.26 and the consensus of $3.23.
For earnings history and earnings-related data on Danaher Corp. (DHR) click here.
Danaher Corp. sees Q4 2012 EPS of $0.80-0.85, versus the consensus of $0.88.
Danaher Corp. sees FY2012 EPS of $3.14-3.19, versus prior guidance of $3.19-3.26 and the consensus of $3.23.
For earnings history and earnings-related data on Danaher Corp. (DHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Zenas BioPharma, Inc. (ZBIO) Reports Q2 Loss of $1.77
- Intuitive Machines, Inc. (LUNR) Misses Q2 EPS by 20c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
